VANI Stock Forecast: Vivani Medical, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$1.09
+3.81% on the day

The median 12-month analyst price target for Vivani Medical, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 44 of 100 as at 18 Nov 2026 — in the lower half.

Market cap
$94.7M
Ticker Nerd rank
44/ 100
Median analyst target
$4.00
Analysts covering
3
Revenue$0.0
Operating income−$6.9M
Net income−$6.4M
Free cash flow−$6.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+10.9%
1M
−2.7%
YTD
−11.4%
1Y
−20.4%
From 52W high
−31.9%
From 52W low
+16.2%
$0.94
$1.60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Vivani Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
44/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
65
Volatility
56
Momentum
52
Issuance
48
Value
48
Revisions
44
Accruals
38
Quality
24

Growth (65): Sales and profits are climbing, and climbing faster than before.

Quality (24): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VANI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VANI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26VANIHigh $4.00Median $4.00Low $3.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$3.50
Low
$4.00
Median
$4.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 June 2026Lake StreetInitiatesBuy$4.00
31 Mar 2026HC Wainwright & Co.MaintainsBuy—
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
16 Apr 2025HC Wainwright & Co.ReiteratesBuy—
4 Apr 2025HC Wainwright & Co.ReiteratesBuy—
26 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Nov 2024HC Wainwright & Co.InitiatesBuy—
5 Dec 2022ThinkEquityInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VANI.

Market Radar

This page is one stock. Monday covers all of them.

VANI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VANI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, Vivani Medical, Inc. returned −20.4% against +9.2% for the S&P 500, dividends included.

VANI vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26VANIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VANI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
5.1×

Cheaper than 19% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−220.4%

Higher than 7% of US stocks

Return on assets
−48.5%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vivani Medical, Inc. has a market value of $94.7M and an enterprise value of $86.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$26.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$26.5M.

  • Shares outstanding: 89.4M.

  • Vivani Medical, Inc. employs 42 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

VANI and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VANIVivani Medical, Inc.$94.7M44
PMVPPMV Pharmaceuticals, Inc.$92.1M59
ZURAZura Bio Ltd.$91.6M15
ANIXAnixa Biosciences, Inc.$90.9M61
EQEquillium, Inc.$90.6M52
OTLKOutlook Therapeutics, Inc.$99.3M3
VYGRVoyager Therapeutics, Inc.$99.5M61

Take a look at VANI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Vivani Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about VANI

What is the VANI stock price forecast for 2026-2027?

The median 12-month analyst price target for Vivani Medical, Inc. is $4, with estimates ranging from $3.5 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VANI stock a buy right now?

Of the 3 analysts covering Vivani Medical, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vivani Medical, Inc. 44 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VANI?

As at 18 Nov 2026, Vivani Medical, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (65 of 100).

Will VANI stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $4, and Ticker Nerd's factor model ranks Vivani Medical, Inc. 44 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VANI stock forecast for 2030?

No analyst covering Vivani Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VANI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $4 over the next 12 months.

How has VANI stock performed over the past year?

Vivani Medical, Inc. returned -20.4% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vivani Medical, Inc. do?

Vivani Medical Inc. is a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting subdermal drug implants using its proprietary NanoPortal technology. The company’s current work centers on implant-based therapies designed to deliver medicines steadily over extended periods, with an emphasis on improving medication adherence and tolerability in chronic diseases.

Company

About Vivani Medical, Inc.

Vivani Medical Inc. is a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting subdermal drug implants using its proprietary NanoPortal technology. The company’s current work centers on implant-based therapies designed to deliver medicines steadily over extended periods, with an emphasis on improving medication adherence and tolerability in chronic diseases. Its product pipeline includes GLP-1-based implants under development for obesity, chronic weight management, and type 2 diabetes, reflecting a focus on metabolic health applications. Vivani Medical also operates a neuromodulation segment, broadening its presence in advanced implantable medical technologies. Headquartered in Alameda, California, the company plays a specialized role in the drug-delivery market by addressing challenges associated with frequent oral or injectable dosing through long-duration implant solutions.

CEO Dr. Adam Mendelsohn Ph.D. · 42 employees · United States · https://www.vivani.com